Comments & Discussion

Boston University moderates comments to facilitate an informed, substantive, civil conversation. Abusive, profane, self-promotional, misleading, incoherent or off-topic comments will be rejected. Moderators are staffed during regular business hours (EST) and can only accept comments written in English. Statistics or facts must include a citation or a link to the citation.

There are 5 comments on Biogen’s New Alzheimer’s Drug Is “Hugely Important,” “One of the Biggest Moments” in 20 Years

  1. I was very surprised by this article after hearing that the review panel was set to strongly recommend against approving this drug. The interview I heard said the effects in the positive study were minuscule and that the other study was firmly negative. And here is an article in science news:
    What is the truth and is trump’s FDA pushing for approval against better evidence?
    Also see link within science news article to a perspective article by the review panel published in Alzheimer and Dementia.

    1. The improvements in the positive study suggest patients could get 2-3 more years of getting dressed by themselves, driving, managing finances, and playing with grandkids. For older AD patients, this could very much be worth it. Pos study results were significant in a number of improvement categories for the high dose, with apparent efficacy fading perfectly in line with decreasing dose levels down to placebo.
      Negative trial results were bad, but Biogen explanation actually makes some sense. Pos trial started weeks after neg trial. Weeks in, Biogen amended the protocol and raised the high dose. Therefore, those in the pos trial received more high doses than patients in the neg trial, because neg trial patients already had been given their first several doses before protocol amendment raised the dose.

  2. My husband has advanced Alz. He is in a wheelchair, but has become stronger, pushes himself with his legs; helps push himself back in wheelchair; saw him transferred with help of only one nurse into a chair with arms so he could eat at the table with others. His ego went way way up! He talks about me and recognizes me even from a distance. He shakes badly sometimes which I remedy by messaging his neck and shoulders; then it usually subsides. He still tells when he wants to use the toilet and if nurse comes soon enough, he does not have an accident. Very forgetful, but wants to read headlines in daily paper; can identify an object by choosing 3 or 4
    clue words (no picture involved). He loves Bingo; music, etc. If I bring him a flashlight or 2 and extra bulbs & batteries, he chooses the right ones for each and realizes success in getting them to light again. He reads very
    slowly but enjoys farm mags that tell of new innovations. He taught 3 math levels, basic electricity, physics, and metallurgy, 30 yrs in a post high school trades/vocational school. Also 2 or 3 yrs at WISU in astronomy & physics, He also was in charge of the observatory there. He also rec’d. trade school diploma post high school in electrical trades; after college he received Masters in Sciences from Drake University. ( In June we will have been married 60 yrs.) I am his wife Dorothy. Hope he might be a candidate for aducanumab or another drug to untangle his tau. A miracle, I hope!

  3. I participated in a study last year (ending in November 2020) of a trial med for Altzheimer’s and feel it made a major difference in my case. I’m praying ths is the same drug as that. So far I haven’t had any decline since the trial ended. Let’s keep our fingers crossed that this drug gets fast-tracked to help the millions of us diagnosed with Altzheimer’s.

    1. Susan Dulaney….hello…can you tell me which drug you are taking? My 74 year old brother has mild dementia and I would love for you to tell me which drug this is. This would be so helpful and a blessing if it works. Please contact me with this information if possible.


      Robert Douglas Brown

Post a comment.

Your email address will not be published. Required fields are marked *